<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01210482</url>
  </required_header>
  <id_info>
    <org_study_id>3066K5-4406</org_study_id>
    <secondary_id>B1771015</secondary_id>
    <nct_id>NCT01210482</nct_id>
    <nct_alias>NCT01420601</nct_alias>
  </id_info>
  <brief_title>Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)</brief_title>
  <official_title>Basis Plan For Postmarketing Survelillances, Etc. Of New Ethical Drugs For Torisel</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this investigation is to determine the following items in all patients
      receiving Torisel for a certain period after marketing:

        1. Confirmation of efficacy and safety for medical practice use.

        2. Investigation of factors that may influence the incidence of adverse events
           (Particularly priority investigation items).

        3. Investigation of the incidence status and the risk factors for interstitial lung
           diseases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Implemented as a Drug Use Investigation by Central Registration System
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2010</start_date>
  <completion_date type="Actual">March 2018</completion_date>
  <primary_completion_date type="Actual">March 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of adverse events</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Adverse events not expected from Japanese Package Insert</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Investigation of the incidence status and the risk factors for interstitial lung diseases</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Response rate (Responsive cases: CR, PR, PD, SD)</measure>
    <time_frame>24 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigation of factors that may influence the incidence of adverse events (Particularly priority investigation items)</measure>
    <time_frame>24 weeks</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1022</enrollment>
  <condition>Renal Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Temsirolimus</arm_group_label>
    <description>Patients treated with Torisel (patients with metastatic and/or radically unresectable or advanced renal cell carcinoma)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Temsirolimus</intervention_name>
    <description>The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30~60 minutes. The dosage is to be appropriately reduced according to patients' status.</description>
    <arm_group_label>Temsirolimus</arm_group_label>
    <other_name>Torisel</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients treated with Torisel (patients with metastatic and/or radically unresectable or
        advanced renal cell carcinoma).
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients treated with Torisel (patients with metastatic and/or radically unresectable
             or advanced renal cell carcinoma).

        Exclusion Criteria:

          -  Patients not administered Torisel.

          -  Patients with a history of severe hypersensitivity to temsirolimus, sirolimus
             derivative, or any of their components and/or derivatives.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyusyu University Hospital</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka PREF</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3066K5-4406&amp;StudyName=Temsirolimus%20%28Torisel%29%20Drug%20Use%20Investigation%20%28Regulatory%20Post%20Marketing%20Commitment%20Plan%29</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>September 27, 2010</study_first_submitted>
  <study_first_submitted_qc>September 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 28, 2010</study_first_posted>
  <last_update_submitted>September 14, 2018</last_update_submitted>
  <last_update_submitted_qc>September 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Torisel</keyword>
  <keyword>Regulatory Post Marketing Commitment Plan</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 8, 2019</submitted>
    <returned>June 17, 2019</returned>
    <submitted>June 27, 2019</submitted>
    <returned>August 28, 2019</returned>
    <submitted>September 24, 2019</submitted>
    <returned>October 17, 2019</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

